Mechanism of Action


MoA of anti-immune checkpoint antibodies (Cancer Immunotherapy).

Service Details
Assay Types Immune cell stimulation assay, MLR
Stimulator CD3/CD28 beads (or anti-CD3 and anti-CD28 antibodies), PMA/ionomycin, LPS, TNF-α, IL-1β, IL-2, Antigens, Mature dendritic cells (mDC)
Responder PBMC, CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, Treg cells, DC, Macrophages
Assessment Cell proliferation (CellTiter-Glo, CFSE), Cytokine release (ELISA/Luminex), Immunophenotyping

Service Features and Advantages

  • A professional team with extensive project experiences from hundreds of projects;
  • Free negative and positive antibody controls;
  • Valid source of primary cells, approved BSL-2 laboratories, IND-filing complied;
  • Multiple IQ, OQ and PQ-certified plate readers with audit trail functions;
  • Provide customized services according to client’s needs with guaranteed delivery.

Please download the project evaluation form, fill it and send it to us for an evaluation

Case Study

Case 1. Characterizations of OX40 antibody by T cell stimulation assay

OX40 receptors are co-stimulatory immune checkpoints on activated immune cells. Triggering OX40-mediated signaling pathways on T cells leads to enhanced cytokine production and T cell expansion.

  • 案例1
  • 案例2

Figure 1. Anti-OX40 antibody enhanced IFN-y production (left) and cell proliferation of CD4+ T cells (right) in a dose-dependent manner.

Case 2. Characterizations of PD-1 antibody by MLR assay

PD1/PDL1 pathway is a typical mechanism of tumor immune escape. PD1/PDL1 inhibitors boost anti-tumor immunity through recovering adaptive immune responses.

  • 案例2
  • 案例2

Figure 2. Anti-PD1 antibody enhanced IL-2 (left) and IFN-y (right) productions in MLR assay.